However, in the high- and low-risk groups, we did not observe the expected differences in the key immune checkpoint genes CD274, CTLA-4, and PDCD1, a result that may affect the effect of immunotherapy in COAD patients. Here, CD274 is linked to colon adenocarcinoma.